Home - PDCI Market Access

PDCI Market Access offers highly strategic market access advice and services which support biopharmaceutical manufacturers to achieve timely and optimal pricing and reimbursement for their medicines. This includes:

For more information, please see our Services.

What's New

16

Sep

NEW Report Release: “Issues and Opportunities to Modernize Private Drug Plan Sustainability in an Evolving Market”

Aug

Connect with PDCI Market Access at CDA Symposium 2024

Jun

PMPRB Releases Long Awaited Discussion Guide as Phase 2 of the New Guidelines Consultation Process

Jan

CADTH Update Introduces Streamlined Economic Reports and Launches BIA Template Consultation

Dec

New Issue of INSIGHTS Released

Dec

Happy Holidays from PDCI!

Nov

PMPRB Provides Themes For First Step Of Guidelines Consultation; Announces Appointments Of Two New Board Members

Nov

PMPRB Invites Stakeholder Feedback on Scoping Paper on Themes for New Guidelines

Oct

PMPRB Publishes Final Decision on Amended Interim Guidance

Sep

PDCI Strengthens Leadership to Enhance Real World Evidence (RWE) Services and Strategic Consulting Capabilities

Sep

pCPA Appoints Douglas Clark as its First CEO

Aug

PCPA Seeks Stakeholder Input On Its Proposed Process To Implement CADTH Time-Limited Recommendations

Jul

Updates on PMPRB Activities in June 2023 NEWSletter

Jul

CADTH Announces Changes to Reimbursement Reviews Process & Fee Schedule Update

Jul

PMPRB Launches Consultation on its Amendment to the Interim Guidance RE: New Medicines

May

PDCI’s Webinar Series: Tips for Health Technology Assessment (HTA) Submissions: Plan your Trip, Pack your Bags and Leave on Time

May

Connect with PDCI Market Access at the CADTH Symposium in Ottawa, May 16-18, 2023

Mar

Federal Government Allocates Up to $1.4 Billion to Improve Access to Drugs for Rare Diseases

Mar

PDCI Continues to Grow its Health Economy Capabilities with the Addition of Eric & Nathalie

Mar

Mélanie Bourassa Forcier References “Dialogue of the Deaf” Between PMPRB and Industry Among Reasons for her Resignation from PMPRB

Mar

INESSS Fee Schedule Update; Upcoming CADTH Consultation and Application Process Updates

Feb

Doug Clark Resigns from PMPRB

Feb

PMPRB Board Member Resigns

Feb

PMPRB New Chairperson

Feb

pCPA Recruiting Their First CEO

Dec

Updates to the Quebec Guidelines for Drug Submission and Evaluation

Dec

PMPRB Interim Chairperson Confirms Resignation

Dec

PMPRB’s 2021 Annual Report Shows Worrying Decline in Number of New Medicines Launched in Canada; HDAP Meeting Tentatively Scheduled for Spring 2023

Dec

PDCI Well Wishes for Managing Director Kaitlyn Proulx

Dec

CADTH Pharmaceutical Reviews Update Includes Launch of RWE Guidance Consultation

Nov

PDCI Launches Sharing Page for PMRPB Consultation on Draft Guidelines- Fall 2022

Nov

Fireside Chat: Trends to Watch in 2023
PDCI’s Lunch Time Educational Webinar Series

Nov

CADTH Pharmaceutical Reviews Update Includes Launch of RWE Guidance Consultation

Nov

PDCI Well Wishes for Managing Director Kaitlyn Proulx

Oct

PDCI’s Early Insights on PMPRB Draft Guidelines

Oct

PMPRB Releases Draft Guidelines and Launches 60-day consultation

Aug

PMPRB Implements its Interim Guidelines with Clarifications

Jul

PDCI Launches Sharing Page for PMPRB Consultation Submissions

Jun

PMPRB Updates: Proposed Interim Guidelines Published

Jun

PDCI welcomes François-Xavier Houde to the Team

Jun

PRESS RELEASE: PDCI’s Biopharmaceutical Ecosystem Index: Where does Canada Rank on its Attractiveness for New Medicine Launch

May

PDCI’s Biopharmaceutical Ecosystem Index
Part of a Lunch Time Educational Series

May

CADTH Update: Advice on Real-World Evidence (RWE) by Scientific Advice Program

Apr

The PMPRB to consult on a different set of guidelines

Apr

CADTH: New Clinical Evidence Template Requirement for October 2022 Submissions

Apr

PMPRB 2020 Annual Report Shows Almost 30% Decrease in New Patented Medicines Reported Since 2018

Mar

Supreme Court Dismisses Attorney General’s Application for Leave to Appeal FCA decision in PMPRB Alexion Soliris Matter

Feb

New PDCI Market Access INSIGHTS (Volume 2, Issue 2)

Feb

Quebec Court Strikes 2 of 3 PMPRB Changes

Feb

Reminder: Form 3 filing is due to the PMPRB On March 1, 2022

Jan

Updates to the Ontario Guidelines for Drug Submission and Evaluation

Jan

REGISTER NOW for PDCI’s Webinar: Impact and Implications of the Delayed Regulations and PMPRB Guidelines

Dec

PDCI Year in Review

Dec

Further Delay to the PMPRB Guidelines and amended Regulations

Dec

PDCI’s 2021 Census of Insurers

Dec

New PDCI Market Access INSIGHTS Volume 2, Issue 1

Dec

PMPRB Proposed Amendments to the July 1, 2021 Guidelines

Dec

Consultation Notice: Proposed Framework for a Potential Pan-Canadian Formulary

Dec

CADTH Pharmaceutical Reviews Update- Issue 27

Dec

WHITEPAPER: Uncovering the Hidden Costs of Take-Home Cancer Drugs

Sep

Welcome to the PDCI Team

Aug

John Anacleto Joins PDCI as Director of Private Payer Strategies & Data Insights

Aug

PMPRB: Federal Court of Appeal quashes PMPRB Alexion / Soliris Decision

Jul

Deadline Extended: PMPRB Notice and Comment

Jun

Welcome Jessica Birrell and Rachel Arcand to the PDCI Team!

Jun

Patented Medicines Regulations/PMPRB Guidelines Further Delayed Until January 1, 2022

Jun

Save the Date! PMPRB has Released Upcoming Webinar on June 15th

May

PDCI at ISPOR: Poster Presentation on Oncology Companion Diagnostics

May

PDCI Market Access Releases New Issue of INSIGHTS Magazine Perspectives on Plan Sponsors and New Coverage Insights

May

PMPRB Announces the Guideline Monitoring and Evaluation Plan (GMEP) Consultation

Apr

Breaking News: 2 Reporting Periods for PMPRB MLP Compliance for Grandfathered and Gap Medicines

Apr

NACI Process For Incorporating Economic Evidence Into Federal Vaccine Recommendations Consultation

Mar

CADTH Releases Pharmaceuticals Reviews Update – Issue 22

Mar

Patented Medicine Prices Review Board (PMPRB) 2019 Annual Report Published

Mar

REMINDER: PDCI Sharing Sites for Policy Submissions Open for Contribution!

Mar

PMPRB February 15th Consultation – Decision made for Gap Medicines and Timelines for Compliance

Mar

PDCI Launches Two New Sharing Sites for Policy Submissions: 1. Federal ISED Biomanufacturing Consultation 2. Health Canada National Drugs for Rare Diseases Consultation

Feb

Welcome Chris Boodoo and Hussein El-Khechen to the PDCI Team!

Feb

PDCI Launches Sharing Page for Submissions to the PMPRB Proposed Amendments to the New Guidelines

Jan

PMPRB Proposes Amendments to New Guidelines: Requests Consultation from Stakeholders

Jan

Released: PMPRB11 Potential Sources for Foreign Prices

Jan

Welcome Piraveena Sabesan to PDCI Market Access

Jan

PMPRB Publishes New CPI Factors for 2021 Price Increases

Dec

Patented Medicines Regulations/PMPRB Guidelines Delayed Until July 1, 2021

Dec

PMPRB Webinar on Online Filing Tool (December 7, 2020) – Attachment Included

Dec

PDCI Market Access Joins McKesson Canada

Dec

INESSS Announces the Establishment of a Waiting List for Scientific Evaluations

Dec

Save the Dates! PMPRB has Released Upcoming Webinar Dates on the New Guidelines

Nov

PDCI’s PMPRB Follow-Up Webinar Postponed

Nov

PDCI’s New Associate Director, Pricing & Data Analytics and Manager, Pricing Data

Nov

Welcome Laura Roulston to the PDCI Team!

Nov

PMPRB Public Webinar DELAYED to November 20, 2020

Oct

House of Commons Standing Committee on Health to Undertake Study on PMPRB Guidelines

Oct

PMPRB is Hosting a Public Webinar on November 10

Oct

REMINDER: PDCI is Hosting a Webinar on the PMPRB Final Guidelines

Oct

Final PMPRB Guidelines: A High Level Summary

Oct

PMPRB Final Guidelines To Be Released Friday, October 23rd, 2020. PDCI Webinar Now Scheduled For Thursday, October 29th, 2020.

Oct

PMPRB Final Guidelines Delayed, PDCI Webinar Postponed

Oct

PDCI Webinar: Overview of the Final PMPRB Guidelines

Oct

CADTH Pharmaceutical Reviews Update — Issue 17

Oct

SAVE THE DATE: PDCI Hosting Webinar on PMPRB Final Guidelines

Sep

PDCI Market Access, Connex Health Consulting and H3 Consulting are Pleased to Release the 2020 Private Payer PLA Report!

Sep

PDCI PLA Study Report – PDCI Market Access Inc., Connex Health Consulting, H3 Consulting

Sep

Welcome Mevin Mathew, Nicolas Iragorri and Shabna Mohideen to the PDCI Team!

Sep

Volume 1 Issue 1 Release of PDCI Market Access Insights Journal

Sep

Neil Palmer is Guest Editor, Cell & Gene Therapy Insights Spotlight on Market Access

Sep

Cell & Gene Therapy Insights

Aug

PDCI’s 2020 Census of Insurers Now Available!

Aug

PDCI Launches Sharing Page for Submissions to the PMPRB Draft Guidelines Consultation (Summer 2020)

Jul

REMINDER: PDCI is Hosting a Webinar on the PMPRB Guidelines

Jul

A WEEK FULL OF NEWS AND HAPPENINGS AT PMPRB

Jul

NEW PDCI INFOGRAPHIC: Best Practices for CADTH Request for Reconsideration

Jul

Request for Reconsideration

Jun

PMPRB: Federal Court Quashes Reporting of Third-Party Discounts & Rebates, Upholds other provisions of the Amended Patented Medicines Regulations

Jun

CADTH Releases Pharmaceutical Reviews Update – Issue 16

Jun

New Draft PMPRB Guidelines: A High Level Summary

Jun

Now Released: PMPRB New Draft Guidelines

Jun

Amendment to the Patented Medicines Regulations Published in Canada Gazette II

Jun

PMPRB Guidelines and Regulations Update

May

Delay of Implementation of PMPRB Amended Regulations to January 1, 2021

May

TargetPharma – CADTH Pharmaceutical Review Update 15

Apr

PDCI Launches 2020 Private Payer PLA Study

Apr

Impact of COVID-19-Related Layoffs on Patients’ Access to Group Insurance

Apr

PDCI Market Access Inc. Welcomes Mark Fleming as a Strategic Advisor

Mar

PDCI Acquires Exclusive License for TELUS Health’s Market Access Toolkit Including INSIGHTS Magazine and Census of Insurers

Mar

Government Authorizes Temporary Compulsory Liscensing in Emergency Legislation for Products Needed to Respond to the COVID-19 Emergency

Mar

PMPRB Has Now Published Submissions Received as Part of its Draft Guidelines Consultation

Mar

PDCI Business Operations: Business [Almost] as Usual!

Mar

PMPRB Cancellation of March 18th Policy Forum

Feb

Introducing Between the Lines: A Canadian Pharmaceutical Industry Podcast

Feb

Sharing Responses to the Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation

Feb

Status Summary of Innovative Medicine pCPA Negotiations as of January 31, 2020

Feb

CADTH Releases Pharmaceutical Reviews Update – Issue 13

Feb

PDCI Analysis Estimates Impact of PMPRB Draft Guidelines to be up to $41.8 Billion

Jan

PDCI’s New Associate Director, HTA and Clinical Evaluation

Jan

Status Summary of Innovative Medicine pCPA Negotiations as of December 31, 2019

Jan

PMPRB and “Zero-dollar” Sales

Jan

CADTH Releases Pharmaceutical Reviews Update – Issue 12

Jan

PMPRB Consultation Update and Patentee Webinar

Dec

Happy Holidays from PDCI Market Access!

Dec

Status Summary of Innovative Medicine pCPA Negotiations as of November 30, 2019

Nov

CADTH Releases Pharmaceutical Reviews Update – Issue 11

Nov

PDCI Market Access: PMPRB Reforms Briefing and Strategy Sessions (Toronto and Montreal)

Nov

Status Summary of Innovative Medicine pCPA Negotiations as of October 31, 2019

Nov

CanReValue RWE Webinar & Feedback Opportunity

Oct

INFOGRAPHIC: The Truth About the Federal Drug Pricing Reform

Oct

Keeley Farrell Joins PDCI Market Access!

Oct

STATUS SUMMARY OF INNOVATIVE MEDICINE pCPA NEGOTIATIONS AS OF SEPTEMBER 30, 2019

Oct

PDCI Response to 2019 CADTH Consultations

Sep

PDCI Market Access: PMPRB Workshops (Toronto and Montreal)

Sep

Waleed Adebayo Joins PDCI Market Access!

Aug

CADTH Releases Pharmaceutical Reviews Update 10

Aug

UPCOMING WEBINAR SEPTEMBER 4: 2019 PMPRB Regulation Amendments and Implications

Aug

HDAP 2020 Meeting Dates Released

Aug

Status Summary of Innovative Medicine pCPA Negotiations as of July 31, 2019

Aug

HEALTH CANADA AMENDMENTS TO PMPRB REGULATIONS

Aug

CADTH Releases Pharmaceutical Reviews Update Issue 9

Jul

Status Summary of Innovative Medicine pCPA Negotiations as of June 30, 2019

Jul

PDCI Announces Strategic Partnership with Goeree Consulting Ltd.

Jun

Status Summary of Innovative Medicine pCPA Negotiations as of May 31, 2019

Jun

PMPRB Announces New Board Vice-Chairperson

Jun

Integration of CDIAC Into CADTH’s pCODR Process

Jun

Forthcoming Revised PMPRB Guidelines

Jun

Final report from the Advisory Council on the Implementation of National Pharmacare

May

CADTH Releases Pharmaceutical Review Update 8

May

Status Summary Of Innovative Medicine pCPA Negotiations As Of April 30, 2019

May

Julia Shen Joins PDCI Market Access!

Apr

Helena Koa Joins PDCI Market Access!

Mar

PDCI’s New Associate Director, HTA & Health Economics

Mar

Kimberly Robinson Joins PDCI Market Access!

Mar

Federal Budget 2019 Supporting the Creation of a Canadian Drug Agency

Mar

Status Summary of Innovative Medicine pCPA Negotiations as of February 28, 2019

Mar

Health Canada and CADTH launch new initiative to provide Early Parallel Scientific Advice

Feb

CADTH Pharmaceutical Reviews Update – Issue 5

Feb

Status Summary of Innovative Medicine pCPA Negotiations as of January 31, 2019

Feb

Expensive Drugs for Rare Diseases – Provincial Working Group Consultation

Feb

CADTH Launches New Parallel Scientific Advice Program

Feb

Observations on National Pharmacare from John-Paul Dowson

Jan

Status Summary of Negotiations on Brand Name Drugs as of December 31, 2018

Jan

All 2019 HDAP Meeting Dates Released

Dec

CADTH Releases Pharmaceutical Review Update Issue 4

Dec

Holiday Greetings

Nov

New INESSS Website Launched

Nov

PMPRB October 2018 NEWSletter Released

Oct

Register for the Market Access Summit and Save 20% with PDCI

Oct

Welcome PDCI New Hires!

Oct

REMINDER: PDCI is Sharing Responses to the National Pharmacare Consultation

Aug

PDCI Sharing Responses to Pharmacare Consultation

Aug

PMPRB 2017 Annual Report Released

Jul

ANNOUNCEMENT – Courtney Abunassar

Jul

CADTH Publishes New CDR Guidelines & Therapeutic Review Process, providing Framework to Revise CDEC Recommendations

Jun

Health Canada, CADTH & INESS Collaborate on Aligned Drug Review Processes

Jun

pCPA Releases its Brand Process Guidelines

May

CADTH publishes CDR Update – Issue 136

May

Join PDCI at the 4th Annual Canadian Institute Pharma Symposium & Save 10% off Registration

May

PMPRB’s May 2018 NEWSletter Updates Guideline Reform Timelines

May

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Apr

INESSS Updates Submission Guide, Checklists and Template Forms

Apr

Standing Committee on Health Publishes Report & Recommendations on National Pharmacare

Apr

New pCODR Patient Input Tip Sheet Available

Apr

Saskatchewan Budget 2018-19: Province to Provide HIV Medications at No Cost

Apr

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Apr

INESSS Releases Additional Information on the Evaluation Process

Mar

Reminder: New prices for generics under pCPA/CGPA agreement become effective April 1st, 2018

Mar

CADTH Invites Stakeholder Feedback on Proposed Revisions to the pCODR Clinician Engagement Process

Mar

CADTH Common Drug Review Releases New Update

Mar

PMPRB March 2018 NEWSletter Released

Feb

Federal Finance Minister Unveils Advisory Council on the Implementation of National Pharmacare in Budget 2018

Feb

Québec Gazette Announces Draft Regulations for Implementation of Fees for INESSS Submissions

Feb

CADTH Common Drug Review Releases New Update

Feb

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Feb

PMPRB Form 3 (R&D) Due Date Reminder

Feb

NEW PDCI Report finds Health Canada significantly overstates benefits & underestimates negative impact of its proposed regulatory amendments

Jan

INESSS Releases Additional Information – Requests for Changes of an Administrative Nature

Jan

PMPRB myth busting (I): The imaginary link between Canadian price controls and R&D expenditures

Jan

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Dec

CADTH Common Drug Review Releases New Update

Dec

Happy Holidays from PDCI Market Access

Dec

TODAY at 1 pm: Government of Canada Officials to Speak on Proposed Regulatory Amendments

Dec

PMPRB Releases Guidelines Scoping Paper with Overview of Potential New Framework

Dec

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Dec

Health Canada releases proposed PMPRB Price Regulations – The Charge of the Price Brigade

Dec

PDCI Webinar: Proposed Amendments to Patented Medicines Regulations – What Patentees Need to Know

Dec

Manitoba Health Amends Submission Requirements

Dec

Proposed Amendments to Patented Medicines Regulations Announced

Nov

INESSS Releases Additional Information on the Continuous Evaluation Process

Nov

PDCI’s Top 5 Tips: Block 5

Nov

CADTH Common Drug Review Releases New Update

Nov

2017 Québec City Healthcare Industry Forum

Nov

INESSS Releases Additional Information on the Continuous Evaluation Process

Nov

CADTH Common Drug Review Releases New Update

Nov

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Nov

INESSS Releases Additional Information on the Continuous Evaluation Process

Nov

National Pharmacare: No need for “Repeal & Replace” Canadian edition

Nov

INESSS Releases List of Drug Products Currently Being Reviewed Under the Continuous Evaluation Process

Nov

PMPRB 2016 Annual Report Released

Oct

PDCI is excited to announce another great addition to the PDCI team: John-Paul Dowson, Director, Reimbursement Strategy

Oct

PDCI Welcomes Jennifer Haig as Manager, HTA and Health Economics

Oct

RAMQ: October 2017 Update for the List of Medications

Oct

INESSS Releases Additional Information on the Continuous Evaluation of Drug Products – Mandatory Notification

Oct

CADTH Common Drug Review Releases New Update

Oct

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Sep

PMPRB Hearing Panel Decision Released: Soliris

Sep

INESSS Releases Additional Information on the Continuous Evaluation of Drug Products

Sep

CADTH Common Drug Review Releases New Update

Sep

Revealing Payments to Physicians: “Health Leaders” going down the wrong road with the PMPRB.

Sep

CADTH Common Drug Review Releases New Update

Sep

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Sep

Notice to Manufacturers – Medications Under Review for February 2018 List Update

Aug

NOW LIVE: PDCI’s Information Sharing Webpage: Responses to Health Canada’s Patented Medicines Regulations Consultation

Aug

Sharing Responses on Proposed Amendments to the Patented Medicines Regulations

Aug

Notice to Manufacturers – Clarification of List Update Schedule in 2018

Aug

CADTH Common Drug Review Releases CDR Update – Issue 126

Aug

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Jul

2018 HDAP Meeting Schedule

Jul

CADTH Common Drug Review Releases New Update

Jul

Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program

Jul

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Jun

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Jun

UPDATE: Québec – INESSS Submission Deadline for August 2017

Jun

CADTH Common Drug Review Releases New Update

Jun

PDCI Market Access Webinar: Information Session for Industry on New INESSS Submission Guidelines and Implementation of Pre-NOC Review Procedure

Jun

NEW: INESSS Releases New Submission Guidelines – Implementation of Pre-NOC Review Procedure

May

The PMPRB Releases its May 2017 NEWSletter

May

PDCI Market Access Webinar: Information Session for Industry on Proposed Amendments to Patented Medicines Regulations

May

Patented Medicines Regulations Consultation Open

May

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

May

PDCI Welcomes Strategic Partner John-Paul Dowson!

May

Join PDCI at 3rd Annual Canadian Institute Pharma Symposium

Apr

New NPDUIS Report Released – PMPRB Meds Entry Watch

Apr

New INESSS Questionnaires Released for Medicines Under Review

Apr

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Mar

CADTH’s Updated Guidelines for the Economic Evaluation of Health Technologies – 4th Edition Now Available

Mar

New CADTH Processes and March Newsletter

Mar

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Mar

CADTH Special Event: New Guidelines for the Economic Evaluation of Health Technologies: Canada

Mar

INESSS Manufacturer Appointments

Feb

PMPRB Form 3 Reminder

Feb

Kaitlyn Proulx appointed Managing Director

Dec

Health Canada Releases Guidance Document for Biosimilar Biologic Drug Submissions

Dec

PMPRB’s Phase 1 of Rethinking the Guidelines Public Comments Now Available

Dec

Alberta Changes Special Authorization Criteria for Coverage of INFLECTRA™ (infliximab)

Nov

Ontario Public Drug Programs Funds New Indications for INFLECTRA™ (infliximab)

Nov

PMPRB Vice Chair Re-appointed

Oct

Registration is Open for CAHR’s 6th Annual National Day

Oct

INESSS Manufacturer Appointments

Oct

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Oct

Application of Generic Substitution to the Exceptional Access Program (EAP)

Oct

Addendum #1 to Ontario Guidelines for Drug Submission and Evaluation to the Ontario Public Drug Programs

Sep

Alberta Releases New Amendments to Price Policy

Sep

Ontario Releases New Amendments to Regulation 201/96 under the ODBA Regulation and Regulation 935 under the DIDFA Regulation

Sep

Ontario Releases Updated Guidelines for Drug Submission and Evaluation 2016

Sep

Feedback on Proposed Revisions to Patient Input Template for CDR and pCODR

Sep

The pCPA: Negotiations Status Update

Aug

Registration is Underway for the CAHR Market Access 201 Course

Aug

PDCI Market Access WEBINAR ‒ Possible 2nd Session September 8, 2016 (date tentative)

Aug

PMPRB 2015 Annual Report Released

Aug

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Aug

PDCI Market Access WEBINAR ‒ Information Session on the PMPRB Guidelines Modernization Discussion Paper

Aug

PDCI Market Access WEBINAR ‒ Information Session on the PMPRB Guidelines Modernization Discussion Paper

Aug

The PMPRB Releases its July 2016 NEWSletter

Jul

SAVE THE DATE

Jul

PMPRB 2015 Annual Report

Jul

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

Jul

PMPRB Guideline Modernization – PDCI to hold Industry Information Sessions in August / September

Jun

PMPRB – Discussion Paper Released – Board Down to 2 Board Members as of June 27 – 2015 Annual Report Board Delayed

Jun

PDCI Releases NEW Report on pCPA Best Practices, Trends and Outlook

Jun

BC PharmaCare Upcoming Modernization of the Reference Drug Program

Jun

RAMQ: June 2016 Update for the List of Medications

May

CADTH CDR and pCODR Engagement with the pCPA

May

Nova Scotia Pharmacare Funds INFLECTRA™ (infliximab)

May

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

May

CADTH Releases Recommendations Report for Anti-Vascular Endothelial Growth Factor Drugs for Retinal Conditions

May

The PMPRB Releases its April 2016 NEWSletter

May

Seeking Participation in the 2016 Private Payer PLA Survey

Apr

New Drug Review Process Developed by INESSS for Stable Blood Products

Apr

The pan-Canadian Pharmaceutical Alliance (pCPA) Releases its April 1st, 2016 Update

Apr

The pCPA Releases First Principles for Subsequent Entry Biologics

Mar

New Implementation Dates for Revisions to the Procedure for Voluntary Withdrawal and Providing CDR Review Team’s Responses

Mar

Minimum Period of 120 Calendar Days for Advance Notification of Anticipated Submissions and Resubmissions for CADTH’s CDR and pCODR Programs

Mar

The PMPRB to Implement Next Steps Regarding the Compendium of Policies, Guidelines and Procedures in June 2016

Mar

Ontario’s CED Will No Longer Routinely Evaluate CDR- or pCODR-Reviewed Drug Products

Mar

Ontario Public Drug Programs Funds INFLECTRA™ (infliximab)

Mar

CADTH Call for Patient Input for INFLECTRA™ (Subsequent Entry Biologic)

Mar

CADTH Call for Patient Input for Etanercept SEB

Mar

Proposal to Amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act to Update Cost-Sharing Arrangements for Non-Low Income Seniors under the Ontario Drug Benefit Program

Feb

Update on Procedures for the CADTH Common Drug Review and pan-Canadian Oncology Drug Review: Mandatory Disclosure of a Submitted Drug Price

Feb

pCPA February Update – Federal Drug Plans officially join the pCPA and the full Office team is now in place

Feb

Ontario Listing of Inflectra

Feb

Alexion pCPA Negotiation

Feb

Alberta Health Releases Price Confirmation Tentative Dates

Feb

PMPRB NEW Report: Generics360 – Generic Drugs in Canada, 2014

Feb

Modifications to the Procedure for Filing a Drug Submission Application for Generic Drugs with INESSS

Feb

New Pilot Initiative: Increasing Opportunities for Clinical Input and Feedback in CADTH pan-Canadian Oncology Drug Review Process

Jan

C-MAP™ Canadian Drug Benefit Plans Reference Guide 2016 Edition NOW AVAILABLE!

Dec

PMPRB Releases Strategic Plan 2015-2018

Dec

Patented Medicine Prices Review Board Releases 2014 Annual Report

Dec

Updates to the Guidelines for the Economic Evaluation of Health Technologies: Canada

Dec

Québec Moves to Introduce a Tendering System for Drugs

Dec

Ontario Releases Summary of Minister’s Roundtable on Pharmacare

Nov

PDCI Strategic Advice Services for Product Listing Agreements

Nov

PMPRB wins at Federal Court of Appeal – Maintains jurisdiction over patented generic products

Nov

Presentation and Poll Results from PDCI Market Access Product Listing Agreement (PLA) Webinar is Now Available

Oct

CADTH: Extending Deadline on Consultation on Procedures for the CADTH Common Drug Review

Oct

CAHR National Day: National Approaches to Pharma Policy: International & Canadian Perspectives

Oct

PDCI Market Access WEBINAR ‒ Market Access Climate Change: the Evolving Impact of Product Listing Agreements

Oct

QUÉBEC: INESSS Upcoming Meetings with Manufacturers – June 2016 “Liste des médicaments”

Oct

pCPA October Update – Québec officially joins the pCPA & the pCPA Office is now operational

Oct

Expanding the CADTH Drug Review Process to Receive Patient Input Submissions from Individual Patients and Caregivers

Jul

The PMPRB has released its July 2015 NEWSletter

Jul

Ontario Public Drug Programs Division

Jul

Exceptional Response to PDCI/H3 Private Payer PLA Survey

Jun

Private Payer PLA Survey

Jun

Australia’s Pharmaceutical Benefits Advisory Committee Recommends Substitution of Biosimilars

Jun

QUEBEC: INESSS Upcoming Meetings with Manufacturers – February 2016 “Liste des médicaments”

Jun

QUÉBEC – INESSS Submission Deadlines: 2015-2016

May

BC: Updates to BC Drug Review Process and Submission Requirements

May

ON: Amendments to Ontario Regulation 201/96

May

Canadian Organization for Rare Disorders (CORD) to release first ever Rare Disease Strategy

Apr

WIB-Greater Montreal and the Technoparc Montréal Present a Conference on Drug Reimbursement in Quebec

Apr

Updates to the Manufacturer Submission Requirements in the Alberta Drug Benefit List (ADBL)

Apr

CADTH: Guidelines for Manufacturers on pCODR Application Fees Implemented

Mar

Rare Diseases Campaign

Mar

The pan-Canadian Oncology Drug Review (pCODR) is moving

Mar

PDCI Canadian Drug Claims Database FREE TRIAL now available!

Mar

CADTH Revised Category 1 Requirements for Tailored CDR Reviews

Mar

Guidelines for Manufacturers on Application Fees for pCODR

Mar

‘Successful CDR, pCODR & INESSS Submissions’ Workshop CANCELLED

Feb

Pan-Canadian Generics – Centralized Price Confirmation Process

Feb

CADTH Update for Patient Groups — January 2015

Feb

PMPRB Update – January 2015 NEWSletter

Jan

Drug products undergoing evaluation for the June 2015 “Liste des médicaments”

Jan

CDEC Final Recommendation for Inflectra Posted

Dec

Happy Holidays from PDCI!

Nov

PMPRB Has Released its October 2014 NEWSletter

Nov

Proposed Regulation Amendments to Establish a Pricing Framework for Generic Products

Nov

PDCI Career Opportunity

Nov

Voluntary Compliance Undertaking of Valeant Canada LP to PMPRB

Oct

Patented Medicines Prices Review Board (PMPRB) Outreach Sessions

Oct

Meetings with Manufacturers for the June 2015 “Liste des médicaments”

Oct

IBM “Pan Canadian Drugs Negotiation Report” Now Available

Oct

Welcome Anita!

Oct

CADTH Updates for Patient Groups

Oct

PMPRB: The PMPRB Launches its New Website

Oct

QUEBEC: October Update for the “Liste des médicaments”

Sep

PMPRB: New enhanced PMPRB website coming soon

Sep

PMPRB: 2013 Annual Report Released

Sep

CADTH: Revised Guidelines for Manufacturers on Application Fees

Aug

15th Anniversary Edition of the C-MAP™ Canadian Drug Benefit Plans Reference Guide

Aug

CADTH Direct-Acting Antivirals for Chronic Hepatitis C Genotype 1

Aug

PMPRB has released its July 2014 NEWSletter

Jul

CADTH: Feedback Requested on Industry Application Fee Guidelines

Jul

CADTH: CDR Update – Issue 106

Jul

New Brunswick: Rare diseases drug plan established

Jul

pCODR: Summary Report from Stakeholder Consultations on Transfer of pCODR to CADTH

Jul

PMPRB 2013 Annual Report Delayed

Jul

CADTH: CDR Update – Issue 105 – Patient Input

Jul

QUEBEC: INESSS to have meetings with manufacturers for February 2015 Liste des médicaments update

Jun

PMPRB Federal Court Decision Appealed

Jun

QUEBEC: Submission deadlines published

May

PMPRB jurisdiction does not extend to Generics (Federal Court Decisions)

May

Update on pCODR Procedures and Guidelines Consultation

May

CADTH: Common Drug Review (CDR) Update – Issue 104

May

Invitation to attend PMPRB Outreach sessions

May

Common Drug Review (CDR) introduces new application fee for submissions

May

The PMPRB releases the April 2014 issue of its NEWSletter

May

Québec: Update to the Liste de médicaments

May

CADTH: CDEC to review Drugs for Rare Diseases via “enhanced” CDR process

Feb

Actual CPI in 2013 and implications for PMPRB price compliance

Feb

Second phase of generic pricing policy implemented yesterday

Feb

Premier Announces New Catastrophic Drug Coverage Program

Feb

Generic drug prices drop to 35 per cent of brand

Feb

Provincial government invests $2.4 million in health research

Feb

INESSS to have meetings with manufacturers for June 2014 Liste des médicaments update

Feb

Update to the Liste de médicaments

Feb

High-income seniors to pay more for drugs

Feb

Price for top 10 generic drugs cut to 20% of brand price

Feb

New drugs on formulary expected to save $10 million/year

Feb

Province announces it will reimburse 100% of the costs of oral cancer drugs

Feb

120 new drugs added to Pharmacare last month

Feb

Some seniors’ and children’s prescriptions to cost more

Feb

Online processing to help Saskatchewan-based travellers receive six-month supplies of drugs

Feb

Province introduces Pharmaceutical Services Act

Feb

Drug manufacturer submission deadlines for listing on the AHWDBL have been updated

PDCI Market Access offers highly strategic market access advice and services which support biopharmaceutical manufacturers to achieve timely and optimal pricing and reimbursement for their medicines. This includes:

Developing EffectiveP&R Strategies

Establishing OptimalPricing

DemonstratingValue

Achieving TimelyMarket Access

What's New

16

Sep

21

Aug

28

Jun

31

Jan

20

Dec

19

Dec

14

Nov

13

Nov

02

Oct

08

Sep

05

Sep

03

Aug

11

Jul

11

Jul

11

Jul

02

May

01

May

23

Mar

07

Mar

07

Mar

01

Mar

24

Feb

24

Feb

13

Feb

13

Feb

20

Dec

19

Dec

05

Dec

05

Dec

05

Dec

22

Nov

22

Nov

22

Nov

22

Nov

13

Oct

06

Oct

19

Aug

Developing Effective
P&R Strategies

Establishing Optimal
Pricing

Demonstrating
Value

Achieving Timely
Market Access